Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

Maureen A. Smythe, Jennifer Priziola, Paul P. Dobesh, Diane Wirth, Adam Cuker, Ann K. Wittkowsky

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.

Original languageEnglish (US)
Pages (from-to)165-186
Number of pages22
JournalJournal of Thrombosis and Thrombolysis
Volume41
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Venous Thromboembolism
Anticoagulants
Heparin
Low Molecular Weight Heparin
Guidelines
Expert Testimony
Therapeutics
Thrombocytopenia
Uncertainty
Outpatients
Hemorrhage
Kidney
Weights and Measures
Incidence
Population
fondaparinux

Keywords

  • Anticoagulation
  • Dalteparin
  • Direct oral anticoagulants (DOAC)
  • Enoxaparin
  • Fondaparinux
  • Heparin
  • Low molecular weight heparin
  • New oral anticoagulants (NOAC)
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. / Smythe, Maureen A.; Priziola, Jennifer; Dobesh, Paul P.; Wirth, Diane; Cuker, Adam; Wittkowsky, Ann K.

In: Journal of Thrombosis and Thrombolysis, Vol. 41, No. 1, 01.01.2016, p. 165-186.

Research output: Contribution to journalArticle

Smythe, Maureen A. ; Priziola, Jennifer ; Dobesh, Paul P. ; Wirth, Diane ; Cuker, Adam ; Wittkowsky, Ann K. / Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. In: Journal of Thrombosis and Thrombolysis. 2016 ; Vol. 41, No. 1. pp. 165-186.
@article{18564709ca06479caa663b091d5e3828,
title = "Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism",
abstract = "Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.",
keywords = "Anticoagulation, Dalteparin, Direct oral anticoagulants (DOAC), Enoxaparin, Fondaparinux, Heparin, Low molecular weight heparin, New oral anticoagulants (NOAC), Venous thromboembolism",
author = "Smythe, {Maureen A.} and Jennifer Priziola and Dobesh, {Paul P.} and Diane Wirth and Adam Cuker and Wittkowsky, {Ann K.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s11239-015-1315-2",
language = "English (US)",
volume = "41",
pages = "165--186",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

AU - Smythe, Maureen A.

AU - Priziola, Jennifer

AU - Dobesh, Paul P.

AU - Wirth, Diane

AU - Cuker, Adam

AU - Wittkowsky, Ann K.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.

AB - Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.

KW - Anticoagulation

KW - Dalteparin

KW - Direct oral anticoagulants (DOAC)

KW - Enoxaparin

KW - Fondaparinux

KW - Heparin

KW - Low molecular weight heparin

KW - New oral anticoagulants (NOAC)

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84954458458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954458458&partnerID=8YFLogxK

U2 - 10.1007/s11239-015-1315-2

DO - 10.1007/s11239-015-1315-2

M3 - Article

C2 - 26780745

AN - SCOPUS:84954458458

VL - 41

SP - 165

EP - 186

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -